Journal of the Chinese Medical Association
Volume 69, Issue 9 , Pages 397-403, September 2006

Lanreotide on Collateral Response to Endothelin-1 and Vasopressin in Cirrhotic Rats

  • Hui-Chun Huang

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Sun-Sang Wang

      Affiliations

    • Taipei Municipal Gan-Dau Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Fa-Yauh Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • Division of General Medicine, Department of Medicine, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Fa-Yauh Lee, Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.
    • ,
  • Full-Young Chang

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Han-Chieh Lin

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Ming-Chieh Hou

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Ying-Ying Yang

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • Division of General Medicine, Department of Medicine, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Shou-Dong Lee

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

Received 26 January 2006; accepted 12 July 2006.

Article Outline

Background

Portosystemic collaterals in cirrhosis are often complicated with hemorrhage. Endothelin-1 (ET-1) and argi-nine vasopressin (AVP) have been shown to directly constrict collaterals of portal hypertensive rats. Furthermore, octreotide, a long-acting somatostatin analog, enhances ET-1-related collateral vasoconstriction if administered in the perfusate before ET-1 incubation. However, long-term effects of somatostatin analogs on collateral response to ET-1 and AVP remain unclarified. This study investigated the effects of lanreotide (a longer-acting somatostatin analog when compared with octreotide) on the portosystemic collateral vascular reactiveness to ET-1 and AVP in cirrhotic rats.

Methods

Liver cirrhosis was induced in Sprague-Dawley rats by common bile duct ligation (BDL). On the 33rd day after BDL, rats received 1 intramuscular injection with lanreotide (10 mg/kg) or distilled water. On the 43rd day after BDL, systemic, and portal hemodynamics were evaluated. By an in situ perfusion model, ET-1 (10−10 −10−7 mol/L) and AVP (10−10 −3 × 10−7 mol/L) were applied to assess the collateral responses.

Results

Heart rate, mean arterial pressure, and portal pressure were not modified by lanreotide. Lanreotide pretreat-ment enhanced collateral vascular response to ET-1 and reached statistical significance at 10−7 mol/L without inducing changes to AVP.

Conclusion

Lanreotide augmented the collateral vascular responsiveness to ET-1 but not to AVP in cirrhotic rats.

Key Words:  endothelin-1 , lanreotide , liver cirrhosis , portosystemic shunting , vasopressin

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Kravetz D , Cummings SA , Groszmann RJ . Hyposensitivity to vasopressin in a hemorrhaged-transfused rat model of portal hypertension . Gastroenterology . 1987;93:170–175
  2. Valla D , Girod C , Lee SS , Braillon A , Lebrec D . Lack of vaso-pressin action on splanchnic hemodynamics during bleeding: a study in conscious, portal hypertensive rats . Hepatology . 1988;8:10–15
  3. Burroughs AK , McCormick PA , Hughes MD , Sprengers D , D'Heygere F , McIntyre N . Randomised double-blind, placebo controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal bleeding . Gastroenterology . 1990;99:1388–1395
  4. Hwang SJ, Lin HC, Chang CF, Lee FY, Lu CW, Hsia HC, et al  A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding . J Hepatol . 1992;16:320–325
  5. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagons in portal hypertensive rats . Am J Physiol . 1988;254:322–328
  6. Sieber CC , Lee FY , Groszmann RJ . Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats . Hepatology . 1996;23:1218–1223
  7. Huang YT , Tsai JF , Liu TB , Hong CY , Yang MC , Lin HC . Chronic administration of octreotide increase vascular responsiveness in rats with portal hypertension . Clin Sci . 1996;91:601–606
  8. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Lin HJ, et al  Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis . Clin Sci . 1998;94:367–371
  9. Londong JE , Angerer M , Kutz K , Landgraf R , Londong V . Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration . Gastroenterology . 1989;96:713–722
  10. Lamberts SWJ , van der Lely AJ , de Herder WW , Hofland LJ . Octreotide . N Engl J Med . 1996;334:246–254
  11. Wiest R , Tsai MH , Groszmann RJ . Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats . Gastroenterology . 2001;120:975–983
  12. Alam I , Bass NM , Bacchetti P , Gee L , Rockey DC . Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites . Am J Gastroenterol . 2000;95:199–203
  13. Kuddus RH , Nalesnik MA , Subbotin VM , Rao AS , Gandhi CR . Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis . J Hepatol . 2000;33:725–732
  14. Rockey DC , Weisiger RA . Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance . Hepatology . 1996;24:233–240
  15. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, et al  Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats . Hepatology . 2001;33:816–820
  16. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Hou MC, et al  Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats . Eur J Clin Invest . 2004;34:290–296
  17. Huang HC, Lee FY, Chan CC, Chang FY, Wang SS, Lin HC, et al  Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats . J Hepatol . 2002;36:163–168
  18. Westaby D , Gimson A , Hayes PC , Williams R . Haemodynamic response to intravenous vasopressin and nitroglycerin in portal hypertension . Gut . 1988;29:327–377
  19. Iwao T, Toyonaga A, Oho K, Shigemori H, Sakai T, Tayama C, et al  Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow . J Hepatol . 1996;25:491–497
  20. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al  Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin . Hepatology . 1999;30:630–635
  21. Wang SS, Chan CC, Lee FY, Chang FY, Lin HC, Chen CT, et al  Effects of long-term octreotide treatment on the response of portal-systemic collaterals to vasopressin in portal hypertensive rats . Eur J Clin Invest . 2002;32:316–321
  22. Karalis K , Mastorakos G , Chrousos GP , Tolis G . Somatostatin analogues suppress the inflammatory reaction in vivo . J Clin Invest . 1994;93:2000–2006
  23. Franco F , Gigou M , Szekely AM , Bismuth H . Portal hypertension after bile duct obstruction. Effect of the bile diversion on portal pressure in the rat . Arch Surg . 1979;114:1064–1067
  24. Cameron GR , Hasan SM . Disturbances of structure and function in the liver as the result of biliary obstruction . J Pathol Bacteriol . 1958;75:33–49
  25. Kountouras J , Billing BH , Scheuer PJ . Prolonged bile duct lig-ation obstruction: a new experimental model of cirrhosis in the rat . Br J Exp Pathol . 1984;65:305–311
  26. Mosca P , Lee FY , Kaumann AJ , Groszmann RJ . Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of the endothelium . Am J Physiol . 1992;263:544–550
  27. Hamilton RL , Berry MN , Williams MC , Severinghaus EM . A simple and inexpensive membrane “lung” for small organ perfusions . J Lipid Res . 1974;15:182–186
  28. Lee FY , Colombato LA , Albillos A , Groszmann RJ . Administration of N?-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats . Gastroenterology . 1993;105:1464–1470
  29. Lee FY, Wang SS, Tsai YT, Lin HJ, Lin HC, Chu CJ, et al  Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats . J Hepatol . 1997;26:687–693
  30. Kuhn JM , Legrand A , Ruiz JM , Obach R , De Ronan J , Thomas F . Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers . Br J Clin Pharmacol . 1994;38:213–219
  31. Mottet C, Sieber CC, Nauer A, Drewe J, Fried R, Larsen F, et al. Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging echo-Doppler study . Hepatology . 1998;27:920–925
  32. Schiedermaier P, Harrison P, Arthur M, Grandt D, Sutton R, Drewe J, et al  Effect of the somatostatin analogue lanreotide on meal-stimulated portal blood flow in patients with liver cirrhosis . Digestion . 2002;65:56–60
  33. Sieber CC, Beglinger C, Bart S, Tschoepl M, Currie G, Larsen F, et al. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion . Clin Pharmacol Ther . 2004;75:70–79
  34. Schiedermaier P , Koch L , Stoffel-Wagner B , Layer G , Sauerbruch T . Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis . Aliment Pharmacol Ther . 2003;18:777–784
  35. Hipkin RW , Friedman J , Clark RB , Eppler CM , Schonbrunn A . Agonist-induced desensitization, internalization, and phospho-rylaton of the sst2A somatostatin receptor . J Biol Chem . 1997;272:13869–13876
  36. Beaumont V , Hepworth MB , Luty JS , Kelly E , Henderson G . Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration . J Biol Chem . 1998;273:33174–33183
  37. Lin HC, Huang YT, Wu HL, Lee WC, Hou MC, Lee FY, et al  Effects of sustained-release lanreotide on hemo-dynamics in rats with portal vein stenosis . J Hepatol . 1999;31:482–488
  38. Sabat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, et al  Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites . Dig Dis Sci . 1998;43:2184–2189
  39. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, et al  Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison . Am J Gastroenterol . 2005;100:631–635
  40. Escorsell A, Bandi JC, Andreu V, Moitinho E, Garcia-Pagan JC, Bosch J, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension . Gastroenterology . 2001;120:161–169
  41. Cerini R , Lee SS , Hadengue A , Koshy A , Girod C , Lebrec D . Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension . Gastroenterology . 1988;94:703–708
  42. Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis . Gastroenterology . 1992;103:229–234
  43. Moller S , Brinch K , Henriksen JH , Becker U . Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis . J Hepatol . 1997;26:1026–1033
  44. Jenkins SA , Nott DM , Baxter JN . Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure . HPB Surg . 1998;11:13–21
  45. Ballas KD, Tzioufa-Asimakopoulou V, Marakis G, Alatsakis MB, Papavasiliou AV, Rafailidis S, et al. Effect of early octreotide administration on the development of esophageal varices in cirrhotic rats . Hepatol Res . 2004;29:104–112
  46. Fort J, Oberti F, Pilette C, Veal N, Gallois Y, Douay O, et al  Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats . Hepatology . 1998;28:1525–1531
  47. Yang YY, Lin HC, Huang YT, Lee TY, Lee WC, Hou MC, et al  Adaptive vasodilatory response after octreotide treatment . Am J Physiol . 2001;281:117–123
  48. Londong JE , Angerer M , Kutz K , Landgraf R , Londong V . Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration . Gastroenterology . 1989;96:713–722
  49. Avgerinos A , Armonis A , Rekoumis G , Manolakopoulos S , Argirakis G , Raptis S . The effect of somatostatin and octreotide on intravascular oesophageal variceal pressure in patients with cirrhosis . J Hepatol . 1995;22:379–380
  50. Primignani M, Carpinelli L, Vazzoler MC, Hall de Lima MC, Nolte A, Marchelli R, et al. Short-term effect of octreotide on intraesophageal variceal pressure: a double-blind placebo controlled study . Eur J Gastroenterol Hepatol . 1994;6:1027–1031
  51. McCormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McIntyre N, et al  Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension . Eur J Gastroenterol Hepatol . 1990;2:489–492
  52. McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, et al  Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study . Hepatology . 1992;16:1180–1186
  53. Tsugawa K, Hashizume M, Migou S, Kishihara F, Kawnaka H, Tomikawa M, et al  Role of nitric oxide and endothelin-1 in a portal hypertensive rat model . Scand J Gastroenterol . 2000;35:1097–1105

PII: S1726-4901(09)70281-3

doi:10.1016/S1726-4901(09)70281-3

Journal of the Chinese Medical Association
Volume 69, Issue 9 , Pages 397-403, September 2006

Article Tools